Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Financing Activities: 2014-2025

Historic Cash from Financing Activities for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to $480,000.

  • Viking Therapeutics' Cash from Financing Activities fell 80.97% to $480,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 99.62%. This contributed to the annual value of $612.5 million for FY2024, which is 125.69% up from last year.
  • Per Viking Therapeutics' latest filing, its Cash from Financing Activities stood at $480,000 for Q3 2025, which was down 5.33% from $507,000 recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Cash from Financing Activities registered a high of $606.0 million during Q1 2024, and its lowest value of -$5.0 million during Q1 2022.
  • Over the past 3 years, Viking Therapeutics' median Cash from Financing Activities value was $1.0 million (recorded in 2024), while the average stood at $80.5 million.
  • In the last 5 years, Viking Therapeutics' Cash from Financing Activities spiked by 22,770.21% in 2022 and then slumped by 840.00% in 2023.
  • Over the past 5 years, Viking Therapeutics' Cash from Financing Activities (Quarterly) stood at $47,000 in 2021, then skyrocketed by 22,770.21% to $10.7 million in 2022, then crashed by 98.25% to $188,000 in 2023, then soared by 431.91% to $1.0 million in 2024, then plummeted by 80.97% to $480,000 in 2025.
  • Its Cash from Financing Activities was $480,000 in Q3 2025, compared to $507,000 in Q2 2025 and $349,000 in Q1 2025.